Medicollect’s competences on recruiting people with diabetes for clinical trials have been in great demand.
Based on clients’ requests Medicollect has decided to add Neurology as a core recruitment service. In UK Medicollect already has a client, Canbex Therapeutics, who is dedicated to treating spasticity in multiple sclerosis.
The company CEO, Torben Lind agrees that it is a bold move:
“It’s clearly a very ambitious strategy to expand that quickly, but we have set the pace high because our clients are happy with our services. We are looking forward to working on other MS projects as well as projects focusing on Alzheimer’s and Parkinson. “
So far, companies such as Novartis, GSK, and the international CRO, Pharm-Olam, have shown interest in using Medicollect’s recruitment services within neurology as well.
After being approved as a supplier to some of the world’s largest pharma companies, Medicollect is proud of also having completed vendor qualification in one of the largest CROs, Medpace.
Medpace has operations in over 50 countries and holds a strong position in diabetes trials. Therefore Medicollect and Medpace match exceptionally well.
Medpace has already asked Medicollect to provide participants for a study on the treatment of diabetic foot ulcers in both the UK and Denmark. We expect a lot from the cooperation with Medpace “says Torben Lind, CEO of Medicollect.